Moscow Exchange · ABIO · IFRS
Artgen biotekh: revenue, profit and cash flow
In 2024, Artgen biotekh had revenue of ₽1.52B and a net profit of ₽215M, according to its consolidated IFRS statements. Here: 12 years of annual reports since 2012, each linked to the original document.
Revenue, 2024
change against 2023
Where the money goes
Of every ₽100 of revenue in 2024, Artgen biotekh spent ₽80.2 on costs and expenses; ₽7.2 went to interest and other items, a tax benefit added ₽1.6, and ₽14.1 was left as net profit.
| In 2024 | Amount | Of revenue |
|---|---|---|
| Revenue | ₽1.52B | 100.0% |
| Costs and expenses | −₽1.22B | 80.2% |
| Operating profit | ₽301M | 19.8% |
| Tax benefit | ₽23.7M | 1.6% |
| Interest and other, net | −₽110M | 7.2% |
| Net profit | ₽215M | 14.1% |
In 2024, Artgen biotekh took in ₽482M of cash from its operations. Of every ₽100 of it, it spent ₽20.7 on capital expenditure, ₽29.2 on dividends, ₽7.5 on buying back its own shares and ₽1.0 on buying other companies. The remaining ₽41.6 was left for other uses: repaying debt, investments or the cash balance.
| In 2024 | Amount | Of operating cash |
|---|---|---|
| Operating cash flow | ₽482M | 100.0% |
| Capital expenditure | −₽99.7M | 20.7% |
| Free cash flow | ₽382M | 79.3% |
| Dividends | −₽141M | 29.2% |
| Buybacks | −₽36M | 7.5% |
| Acquisitions | −₽4.9M | 1.0% |
| Left over | ₽201M | 41.6% |
Revenue and net profit
Revenue went from ₽300M in 2012 to ₽1.52B in 2024. Net loss in 2012, 2014–2016, 2018.
Earnings per share
Basic earnings per share went from −₽1.44 in 2012 to ₽2.32 in 2024.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was ₽382M in 2024, 25.1% of revenue. Negative in 2012, 2015–2016, 2018–2020.
What it owns and who paid for it
At the end of 2024, Artgen biotekh had ₽2.67B of assets, ₽503M of it in cash. They were paid for by ₽568M of borrowings, ₽1.7B of other liabilities and ₽407M of shareholders' equity: equity is 15.3% of the assets.
Net debt
Net debt (borrowings minus cash) was ₽64.9M at the end of 2024. That is 0.2 times its EBITDA of ₽386M (operating profit plus depreciation and amortisation).
Dividends paid
In 2024, Artgen biotekh paid ₽141M in dividends, 65% of its net profit for the year.
The charts could not be loaded; the table below has the same numbers.
Artgen biotekh: annual figures
| Year | Revenue | Operating profit | Net profit | Basic EPS | Operating cash flow | Capital expenditure | Free cash flow | Net debt | Dividends paid | Total assets | Equity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | ₽1.52B | ₽301M | ₽215M | ₽2.32 | ₽482M | ₽99.7M | ₽382M | ₽64.9M | ₽141M | ₽2.67B | ₽407M |
| 2023 | ₽1.37B | ₽276M | ₽169M | ₽1.82 | ₽435M | ₽204M | ₽231M | ₽103M | ₽104M | ₽2.54B | ₽500M |
| 2022 | ₽1.14B | ₽111M | ₽46.1M | ₽0.53 | ₽220M | ₽136M | ₽84.4M | ₽507M | ₽40.1M | ₽2.04B | ₽341M |
| 2021 | ₽1.18B | ₽119M | ₽11.6M | ₽0.16 | ₽281M | ₽153M | ₽128M | ₽301M | ₽30.9M | ₽1.74B | ₽235M |
| 2020* | ₽1.08B | ₽198M | ₽72.9M | ₽0.97 | ₽53.9M | ₽85.6M | −₽31.7M | ₽246M | ₽12.7M | ₽1.51B | ₽194M |
| 2019 | ₽836M | ₽181M | ₽84.6M | ₽1.48 | ₽176M | ₽196M | −₽20.5M | ₽192M | — | ₽1.4B | ₽98.7M |
| 2018* | ₽645M | ₽117M | −₽34.2M | −₽0.24 | ₽19.4M | ₽35.3M | −₽15.9M | ₽308M | — | ₽1.12B | ₽27M |
| 2016 | ₽390M | −₽144M | −₽111M | −₽1.75 | ₽36M | ₽66.9M | −₽30.9M | ₽60.7M | ₽21.3M | ₽1.04B | ₽154M |
| 2015* | ₽311M | −₽95.5M | −₽51.5M | −₽0.83 | ₽4.6M | ₽19.3M | −₽14.7M | ₽63.9M | ₽0 | ₽833M | ₽288M |
| 2014 | ₽359M | −₽51.3M | −₽13.2M | −₽0.22 | ₽38.2M | ₽32.9M | ₽5.37M | ₽27.5M | — | ₽806M | ₽339M |
| 2013 | ₽420M | ₽42.7M | ₽14.7M | ₽0.22 | ₽82.5M | ₽34.5M | ₽48M | ₽109M | — | ₽729M | ₽352M |
| 2012* | ₽300M | −₽32.6M | −₽109M | −₽1.44 | −₽55.5M | ₽32.1M | −₽87.6M | ₽123M | — | ₽683M | ₽337M |
* Taken from the comparative column of the next year's report: the year's own report was not available to us.
Original reports
Every figure on this page comes from the company's own annual statements. The documents, by year:
- 2025 — RAS financial statements (single entity)
- 2024 — IFRS consolidated financial statements
- 2023 — IFRS consolidated financial statements
- 2022 — IFRS consolidated financial statements
- 2021 — IFRS consolidated financial statements
- 2019 — IFRS consolidated financial statements
- 2016 — IFRS consolidated financial statements
- 2015 — IFRS consolidated financial statements
- 2014 — IFRS consolidated financial statements
- 2013 — IFRS consolidated financial statements
How to read these numbers
- A year's figures are as first reported. Companies sometimes restate the previous year in their next report (new accounting standards, discontinued operations); the original documents show both versions.
Source: annual financial statements published by Artgen biotekh (links to the original documents above). Figures read from the documents by BigCapital.
For information only, not investment advice.